Skip to main content

Table 3 Performance of baseline tenascin-C levels to predict disease flares (Cox proportional hazards analysis)

From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

  Univariate analyses Age and sex adjusted analyses
Flare definition HR (95 % CI) p Value HR (95 % CI) p Value
Tenascin as continuous variable     
 (i) New/increased GC 1.39 (1.11–1.73) 0.004 1.37 (1.11–1.70) 0.004
 (ii) New/increased GC or IS 1.25 (1.02–1.52) 0.028 1.23 (1.01–1.49) 0.035
 (iii) Increase in SLEDAI-2 K ≥3 1.19 (0.87–1.63) 0.277 1.21 (0.86–1.68) 0.270
 (iv) BILAG-2004 flare A or B 1.10 (0.91–1.34) 0.323 1.09 (0.89–1.32) 0.403
Tenascin as categorical variable (>659 ng/ml)a  
 (i) New/increased GC 3.77 (1.60–8.88) 0.002 3.57 (1.48–8.59) 0.005
 (ii) New/increased GC or IS 2.45 (1.10–5.46) 0.028 2.23 (0.98–5.08) 0.056
 (iii) Increase in SLEDAI-2 K ≥3 1.42 (0.28–7.21) 0.672 1.52 (0.27–8.64) 0.636
 (iv) BILAG-2004 flare A or B 1.74 (0.75–4.04) 0.197 1.64 (0.70–3.88) 0.257
  1. BILAG-2004 British Isles Lupus Assessment Group disease activity index, CI confidence interval, HR hazard ratio, IS immunosuppressants, GC glucocorticoids, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000
  2. aThe threshold value of 659 ng/ml for tenascin-C (TNC) was generated using receiver operating characteristic curve analysis of the relationship between active systemic lupus erythematosus (SLEDAI-2 K ≥6) and baseline TNC
  3. Boldface type indicates statistically significant values